Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-28 AccNo: 0001493152-26-044451 Size: 231 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
On June 23, 2025, at the 2025 annual meeting of stockholders of Matinas BioPharma Holdings, Inc. (the "Company"), the stockholders approved the authorization of the Board of Directors (the "Board"), in
Matinas BioPharma received a notice from NYSE American on August 31, 2026, stating the company is not in compliance with continued listing standards due to stockholders' equity of $1.8 million (below the required $2.0 million threshold) and losses in five consecutive fiscal years. The company submitted a compliance plan accepted by NYSE American with a deadline of October 2, 2027. Shares will continue trading during the plan period, but delisting proceedings may be initiated if compliance is not achieved.